Outcome |
Relative effect (95% CI) |
Absolute effect (95% CI)1 |
Certainty of the Evidence (GRADE) |
Clinical improvement D28 |
RR: 1.08 (0.76 - 1.53) |
57 more per 1000 (from 171 fewer to 378 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
2 trials
Han MK, 2022; Incyte Corporation 2022
643 participants
|
|
Ruxolitinib 771 per 1,000 (542 - 1000) |
Placebo 714 per 1,000 |
|
Clinical improvement D60 |
Outcome not yet measured or reported
|
|
WHO progression score (level 7 or above) D28 |
RR: 1.01 (0.58 - 1.75) |
1 more per 1000 (from 49 fewer to 88 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Multicentre study conducted across several countries, therefore not downgraded for indirectness Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
1 trials
Han MK, 2022
432 participants
|
|
Ruxolitinib 118 per 1,000 (68 - 205) |
Placebo 117 per 1,000 |
|
WHO progression score (level 7 or above) D60 |
Outcome not yet measured or reported
|
|
All-cause mortality D28 |
RR: 0.79 (0.48 - 1.27) |
43 fewer per 1000 (from 106 fewer to 55 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
2 trials
Han MK, 2022; Incyte Corporation 2022
643 participants
|
|
Ruxolitinib 160 per 1,000 (98 - 258) |
Placebo 203 per 1,000 |
|
All-cause mortality D60 |
Outcome not yet measured or reported
|
|
Viral negative conversion D7 |
Outcome not yet measured or reported
|
|
Adverse events
|
RR: 1.01 (0.85 - 1.19) |
7 more per 1000 (from 98 fewer to 124 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
2 trials
Han MK, 2022; Incyte Corporation 2022
643 participants
|
|
Ruxolitinib 658 per 1,000 (553 - 775) |
Placebo 651 per 1,000 |
|
Serious adverse events
|
RR: 1.09 (0.73 - 1.65) |
12 more per 1000 (from 37 fewer to 88 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
2 trials
Han MK, 2022; Incyte Corporation 2022
643 participants
|
|
Ruxolitinib 148 per 1,000 (99 - 223) |
Placebo 135 per 1,000 |
|
1The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect